Herein, we investigated pair-matched clinical BC samples (treatment-naïve and CRT-recurrent tumors) from the same patient and identified an aberrant BUB1B/BUBR1 expression level in CRT-recurrent clone, which facilitates mutagenic NHEJ activity in response to IR and cisplatin leading to the tumor harboring accumulated mutations. This evidence concerns the gene BUB1B and breast cancer.